Soligenix, Inc. Banner Image

Soligenix, Inc. has reached its limit for free report views

Work for Soligenix, Inc.? Upgrade Your Profile and unlock all your annual reports.

Soligenix, Inc.

  • Ticker SNGX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Soligenix, Inc. Logo Image
  • 11-50 Employees
  • Based in Princeton, New Jersey
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their Specialized BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, their first-in-class innate defense regulatorMore (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).
Soligenix, Inc.

Most Recent Annual Report

Soligenix, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Soligenix, Inc. has reached its limit for free report views.

Older/Archived Annual Reports